The prognostic value of androgen receptor (AR) in HER2-enriched metastatic breast cancer

in Endocrine-Related Cancer

Correspondence should be addressed to Z Yuan: yuanzhy@sysucc.org.cn

*(X Wang, X Bi and Z Huang contributed equally to this work)

Restricted access

The significance of androgen receptor (AR) in metastatic breast cancer (MBC) remains unclear, and it is still largely unknown how AR expression level influences HER2-positive tumors. This study aimed to investigate the prognostic and predictive value of AR in HER2-enriched MBC. Primary and/or paired metastatic tumors of 304 patients with pathologically confirmed HER2-enriched MBC were collected and immunohistochemically assessed for AR expression. The associations of AR and other clinicopathological characteristics were compared using the Chi-square test. Progression-free survival (PFS) and overall survival (OS) were calculated using the Kaplan–Meier method and log-rank test. Cox regression analysis was used to determine independent prognostic factors. AR-positivity with a cut-off value of 10% was observed in 237 (78.0%) cases and was associated with longer PFS, 13.2 months, as compared to that of 8.2 months (P = 0.004) in patients with AR-negativity. Moreover, a significant increase in the 5-year OS rate (65.3% vs 36.2%, P < 0.001) was also observed for patients with AR-positive tumors. Cox regression analysis identified AR-positivity as an independent prognostic factor of both PFS (hazard ratio = 0.71, P = 0.039) and OS (HR = 0.53, P = 0.013). Additionally, for those who received first-line Trastuzumab therapies, prolonged PFS (15.8 months vs 8.2 months, P = 0.005) and 5-year OS rate (66.2% vs 26.2%, P = 0.009) were observed in AR-positive tumors compared to AR-negative ones. In conclusion, AR was identified as an independent prognostic factor for favorable PFS and OS and could also predict the efficacy of first-line Trastuzumab treatment in patients with HER2-enriched MBC.

 

      Society for Endocrinology

Sept 2018 onwards Past Year Past 30 Days
Abstract Views 75 75 75
Full Text Views 8 8 8
PDF Downloads 8 8 8
  • AgoffSNSwansonPELindenHHawesSELawtonTJ 2003 Androgen receptor expression in estrogen receptor-negative breast cancer. Immunohistochemical, clinical, and prognostic associations. American Journal of Clinical Pathology 725731. (https://doi.org/10.1309/42F00D0DJD0J5EDT)

    • Search Google Scholar
    • Export Citation
  • AleskandaranyMAAbduljabbarRAshankytyIElmounaAJerjeesDAliSBuluwelaLDiez-RodriguezMCaldasCGreenAR 2016 Prognostic significance of androgen receptor expression in invasive breast cancer: transcriptomic and protein expression analysis. Breast Cancer Research and Treatment 215227. (https://doi.org/10.1007/s10549-016-3934-5)

    • Search Google Scholar
    • Export Citation
  • ArteagaCLSliwkowskiMXOsborneCKPerezEAPuglisiFGianniL 2011 Treatment of HER2-positive breast cancer: current status and future perspectives. Nature Reviews: Clinical Oncology 1632. (https://doi.org/10.1038/nrclinonc.2011.177)

    • Search Google Scholar
    • Export Citation
  • AsanoYKashiwagiSGotoWTanakaSMorisakiTTakashimaTNodaSOnodaNOhsawaMHirakawaK 2017 Expression and clinical significance of androgen receptor in triple-negative breast cancer. Cancers 9 4. (https://doi.org/10.3390/cancers9010004)

    • Search Google Scholar
    • Export Citation
  • BartonVND’AmatoNCGordonMALindHTSpoelstraNSBabbsBLHeinzREEliasAJedlickaPJacobsenBM 2015 Multiple molecular subtypes of triple-negative breast cancer critically rely on androgen receptor and respond to enzalutamide in vivo. Molecular Cancer Therapeutics 769778. (https://doi.org/10.1158/1535-7163.MCT-14-0926)

    • Search Google Scholar
    • Export Citation
  • BasileDCinauseroMIaconoDPelizzariGBonottoMVitaleMGGerratanaLPuglisiF 2017 Androgen receptor in estrogen receptor positive breast cancer: beyond expression. Cancer Treatment Reviews 1522. (https://doi.org/10.1016/j.ctrv.2017.09.006)

    • Search Google Scholar
    • Export Citation
  • Bozovic-SpasojevicIZardavasDBroheeSAmeyeLFumagalliDAdesFde AzambujaEBarecheYPiccartMPaesmansM 2017 The prognostic role of androgen receptor in patients with early-stage breast cancer: a meta-analysis of clinical and gene expression data. Clinical Cancer Research 27022712. (https://doi.org/10.1158/1078-0432.CCR-16-0979)

    • Search Google Scholar
    • Export Citation
  • CareyLAPerouCMLivasyCADresslerLGCowanDConwayKKaracaGTroesterMATseCKEdmistonS 2006 Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 24922502. (https://doi.org/10.1001/jama.295.21.2492)

    • Search Google Scholar
    • Export Citation
  • ChiaKO’BrienMBrownMLimE 2015 Targeting the androgen receptor in breast cancer. Current Oncology Reports 4. (https://doi.org/10.1007/s11912-014-0427-8)

    • Search Google Scholar
    • Export Citation
  • CollinsLCColeKSMarottiJDHuRSchnittSJTamimiRM 2011 Androgen receptor expression in breast cancer in relation to molecular phenotype: results from the Nurses’ Health Study. Modern Pathology 924931. (https://doi.org/10.1038/modpathol.2011.54)

    • Search Google Scholar
    • Export Citation
  • ElebroKBendahlPOJernstromHBorgquistS 2017 Androgen receptor expression and breast cancer mortality in a population-based prospective cohort. Breast Cancer Research and Treatment 645657. (https://doi.org/10.1007/s10549-017-4343-0)

    • Search Google Scholar
    • Export Citation
  • GiulianoAEConnollyJLEdgeSBMittendorfEARugoHSSolinLJWeaverDLWinchesterDJHortobagyiGN 2017 Breast cancer-major changes in the American Joint Committee on cancer eighth edition cancer staging manual. CA: A Cancer Journal for Clinicians 290303. (https://doi.org/10.3322/caac.21393)

    • Search Google Scholar
    • Export Citation
  • GordonMAD’AmatoNCGuHBabbsBWulfkuhleJPetricoinEFGallagherIDongTTorkkoKLiuB 2017 Synergy between androgen receptor antagonism and inhibition of mTOR and HER2 in breast cancer. Molecular Cancer Therapeutics 13891400. (https://doi.org/10.1158/1535-7163.MCT-17-0111)

    • Search Google Scholar
    • Export Citation
  • GucalpATolaneySIsakoffSJIngleJNLiuMCCareyLABlackwellKRugoHNabellLForeroA 2013 Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic breast cancer. Clinical Cancer Research 55055512. (https://doi.org/10.1158/1078-0432.CCR-12-3327)

    • Search Google Scholar
    • Export Citation
  • HilbornEGacicJFornanderTNordenskjoldBStalOJanssonA 2016 Androgen receptor expression predicts beneficial tamoxifen response in oestrogen receptor-alpha-negative breast cancer. British Journal of Cancer 248255. (https://doi.org/10.1038/bjc.2015.464)

    • Search Google Scholar
    • Export Citation
  • HonmaNHoriiRIwaseTSajiSYounesMItoYAkiyamaF 2012 Clinical importance of androgen receptor in breast cancer patients treated with adjuvant tamoxifen monotherapy. Breast Cancer 20 323330. (https://doi.org/10.1007/s12282-012-0337-2)

    • Search Google Scholar
    • Export Citation
  • KravchenkoJAkushevichISeewaldtVLAbernethyAPLyerlyHK 2011 Breast cancer as heterogeneous disease: contributing factors and carcinogenesis mechanisms. Breast Cancer Research and Treatment 483493. (https://doi.org/10.1007/s10549-011-1347-z)

    • Search Google Scholar
    • Export Citation
  • LeaOAKvinnslandSThorsenT 1989 Improved measurement of androgen receptors in human breast cancer. Cancer Research 71627167.

  • LoiblSMullerBMvon MinckwitzGSchwabeMRollerMDarb-EsfahaniSAtasevenBdu BoisAFissler-EckhoffAGerberB 2011 Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy. Breast Cancer Research and Treatment 477487. (https://doi.org/10.1007/s10549-011-1715-8)

    • Search Google Scholar
    • Export Citation
  • McNamaraKMMooreNLHickeyTESasanoHTilleyWD 2014 Complexities of androgen receptor signalling in breast cancer. Endocrine-Related Cancer T161T181. (https://doi.org/10.1530/ERC-14-0243)

    • Search Google Scholar
    • Export Citation
  • McShaneLMAltmanDGSauerbreiWTaubeSEGionMClarkGM & Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics 2005 REporting recommendations for tumour MARKer prognostic studies (REMARK). British Journal of Cancer 387391. (https://doi.org/10.1038/sj.bjc.6602678)

    • Search Google Scholar
    • Export Citation
  • MoinfarFOkcuMTsybrovskyyORegitnigPLaxSFWeyboraWRatschekMTavassoliFADenkH 2003 Androgen receptors frequently are expressed in breast carcinomas: potential relevance to new therapeutic strategies. Cancer 703711. (https://doi.org/10.1002/cncr.11532)

    • Search Google Scholar
    • Export Citation
  • NCCN 2018 NCCN clinical practice guidelines in oncology: breast cancer. Plymouth Meeting PA USA: National Comprehensive Cancer Network. (available at: https://www.nccn.org/professionals/physician_gls/default.aspx)

    • Search Google Scholar
    • Export Citation
  • NiMChenYLimEWimberlyHBaileySTImaiYRimmDLLiuXSBrownM 2011 Targeting androgen receptor in estrogen receptor-negative breast cancer. Cancer Cell 119131. (https://doi.org/10.1016/j.ccr.2011.05.026)

    • Search Google Scholar
    • Export Citation
  • ParkSKooJParkHSKimJHChoiSYLeeJHParkBWLeeKS 2010 Expression of androgen receptors in primary breast cancer. Annals of Oncology 488492. (https://doi.org/10.1093/annonc/mdp510)

    • Search Google Scholar
    • Export Citation
  • PetersAABuchananGRicciardelliCBianco-MiottoTCenteneraMMHarrisJMJindalSSegaraDJiaLMooreNL 2009 Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer. Cancer Research 61316140. (https://doi.org/10.1158/0008-5472.CAN-09-0452)

    • Search Google Scholar
    • Export Citation
  • PusztaiLVialeGKellyCMHudisCA 2010 Estrogen and HER-2 receptor discordance between primary breast cancer and metastasis. Oncologist 11641168. (https://doi.org/10.1634/theoncologist.2010-0059)

    • Search Google Scholar
    • Export Citation
  • QuQMaoYFeiXCShenKW 2013 The impact of androgen receptor expression on breast cancer survival: a retrospective study and meta-analysis. PLoS ONE e82650. (https://doi.org/10.1371/journal.pone.0082650)

    • Search Google Scholar
    • Export Citation
  • RangelNRondon-LagosMAnnaratoneLOsella-AbateSMetovicJManoMPBerteroLCassoniPSapinoACastellanoI 2018 The role of the AR/ER ratio in ER-positive breast cancer patients. Endocrine-Related Cancer 163172. (https://doi.org/10.1530/ERC-17-0417)

    • Search Google Scholar
    • Export Citation
  • RomondEHPerezEABryantJSumanVJGeyerCEJrDavidsonNETan-ChiuEMartinoSPaikSKaufmanPA 2005 Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. New England Journal of Medicine 16731684. (https://doi.org/10.1056/NEJMoa052122)

    • Search Google Scholar
    • Export Citation
  • SlamonDJLeyland-JonesBShakSFuchsHPatonVBajamondeAFlemingTEiermannWWolterJPegramM 2001 Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. New England Journal of Medicine 783792. (https://doi.org/10.1056/NEJM200103153441101)

    • Search Google Scholar
    • Export Citation
  • SternHM 2012 Improving treatment of HER2-positive cancers: opportunities and challenges. Science Translational Medicine 127rv2. (https://doi.org/10.1126/scitranslmed.3001539)

    • Search Google Scholar
    • Export Citation
  • Vera-BadilloFETempletonAJde GouveiaPDiaz-PadillaIBedardPLAl-MubarakMSerugaBTannockIFOcanaAAmirE 2014 Androgen receptor expression and outcomes in early breast cancer: a systematic review and meta-analysis. Journal of the National Cancer Institute djt319. (https://doi.org/10.1093/jnci/djt319)

    • Search Google Scholar
    • Export Citation
  • WolffACHammondMEHicksDGDowsettMMcShaneLMAllisonKHAllredDCBartlettJMBilousMFitzgibbonsP 2013 Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. Journal of Clinical Oncology 39974013. (https://doi.org/10.1200/JCO.2013.50.9984)

    • Search Google Scholar
    • Export Citation